Scinai Immunotherapeutics to Lead Biopharma Manufacturing Discussion at HealthIL Week 2026

Scinai Immunotherapeutics to Address Biopharma Manufacturing Challenges at HealthIL Week 2026

Scinai Immunotherapeutics Ltd., a biopharmaceutical company specializing in inflammation and immunology therapeutics, announces a significant development as its CEO, Amir Reichman, prepares to co-lead a pivotal roundtable discussion at HealthIL Week 2026. Scheduled for January 19, 2026, at Expo Tel Aviv, the event titled "Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale" aims to stimulate a comprehensive dialogue about Israel's biopharma ecosystem. This is particularly timely given the increasing global demand for efficient and effective biopharmaceutical manufacturing solutions. The roundtable, organized by the Manufacturers Association of Israel, seeks to bring together key stakeholders to assess not only the current state of the industry but also the infrastructure necessary for advancing biopharma manufacturing in the region.

The discussion will focus on several critical aspects, including early-stage development, chemistry, manufacturing, and controls (CMC), as well as clinical manufacturing practices. Participants will evaluate the existing infrastructure for laboratory access and Good Manufacturing Practice (GMP) manufacturing, which are vital for supporting clinical supply chains. By addressing the challenges that biopharma companies face in scaling their operations, the roundtable aims to identify gaps and necessary improvements in Israel's manufacturing landscape. CEO Amir Reichman underscores the importance of this initiative in mapping out the required enhancements to facilitate growth from early clinical phases to commercial manufacturing.

Moreover, the roundtable will delve into global trends impacting the biopharma manufacturing sector, such as the increasing complexity of biologic modalities and shifting regulatory expectations. The involvement of local and international Contract Development and Manufacturing Organizations (CDMOs) will also be scrutinized, as these entities play a critical role in the production process. By fostering collaboration among various stakeholders—including governmental agencies, multinational pharmaceutical companies, and investors—this event aims to create a more cohesive and supportive environment for biopharma development in Israel, ultimately enhancing the country's competitive position in the global market.

In addition to the roundtable, HealthIL Week stands as Israel's leading international conference for healthcare innovation, providing a platform for networking among industry leaders, academics, and governmental representatives. This gathering is crucial for fostering collaborations that can drive advancements in healthcare technologies and biopharmaceutical manufacturing. The participation of Scinai Immunotherapeutics, alongside other industry players, highlights the company’s commitment to addressing the challenges and opportunities within the biopharma landscape in Israel.

As the biopharmaceutical industry continues to evolve, discussions like the one led by Amir Reichman will play a key role in shaping the future of manufacturing capabilities in Israel, benefiting not only local companies but also contributing to the global biopharma supply chain.